Cardiac Science Announces Inclusion in Russell 3000 Index
BOTHELL, Wash., June 30 /PRNewswire-FirstCall/ -- Cardiac Science Corporation , a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced today that it has been selected to join the Russell 3000(R) Index. The Company's addition to the Russell 3000 Index was made effective following the market close on Friday, June 27. Selection to the Russell 3000 index means Cardiac Science is automatically included in the Russell 2000(R) Index, which measures the performance of approximately 2,000 small-cap U.S. securities.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)
"We believe our inclusion in the Russell indexes will provide our company with greater visibility to a broader range of potential investors," said John Hinson, president and chief executive officer of Cardiac Science.
The Russell 3000 Index measures the performance of the largest 3,000 U.S. companies, and is constructed to provide a comprehensive, unbiased and stable barometer of the broad market. The Index is reconstituted annually. The Russell 2000 Index is a subset of the Russell 3000 Index.
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
CONTACT: company, Mike Matysik, Sr. Vice President and CFO of Cardiac
Science Corporation, +1-425-402-2009; or investors, Jenifer Kirtland or
Donald Takaya, +1-415-896-6820, or media, Christopher Gale,
+1-201-646-5431, +1-203-570-4681, cgale@evcgroup.com, all of EVC Group,
Inc., for Cardiac Science Corporation
Web site: http://www.cardiacscience.com/